Key Highlights

  • 0.19 USD is the per-share loss built into the consensus EPS estimate of -0.19 for Neumora Therapeutics, Inc. (NASDAQ:NMRA), due to report third-quarter 2026 results ahead of the opening bell on November 13, 2026.
  • 43.1 million USD was the second-quarter 2026 deficit, or USD 0.23 per share, compared with USD 52.7 million, or USD 0.33 per share, during Q2 2025, as research outlays dropped to USD 29.3 million.
  • 116.8 million USD was the cash on hand at June 30, 2026, down from USD 182.5 million at December 31, 2025, with management expecting it to finance planned operations into third-quarter 2027.
  • 88.87 million USD is the Market Value in the screening snapshot, under USD 100 million, while results from the NMRA-511 and NMRA-898 studies are guided for fourth-quarter and second-half 2026.

What Canadian Investors Can Expect From Neumora Therapeutics, Inc. (NASDAQ:NMRA) on November 13, 2026

The screening snapshot has Neumora Therapeutics, Inc. publishing third-quarter 2026 results before the opening bell on November 13, 2026, with a consensus EPS estimate of -0.19 and a market value of USD 88.87 million. That estimate is a smaller loss than the USD 0.23 per share posted for second-quarter 2026, which hints at continued cost discipline across the business. Coverage supplied no prior-year third-quarter comparison, and the snapshot gave no call time.

Latest Quarter Results and Management Outlook at Neumora Therapeutics, Inc. (NASDAQ:NMRA)

In second-quarter 2026, R&D spending fell to USD 29.3 million from USD 38.7 million, and G&A spending fell to USD 12.9 million from USD 15.3 million. The Deficit over six months was USD 96.5 million against USD 120.7 million, or USD 0.53 per share. Joshua Pinto stepped in as president and CEO of the company, Paul Berns shifted to Executive Chair, and Doron Sagman was appointed chief medical officer. Management intends to file an NMRA-215 IND in fourth-quarter 2026, report NMRA-511 data that quarter, start a Phase 2 trial in Alzheimer's agitation by year-end 2026, and deliver NMRA-898 data in second-half 2026.

Liquidity, Valuation and Risk Factors at Neumora Therapeutics, Inc. (NASDAQ:NMRA)

The second-quarter deficit shrank roughly 18% from the prior year (calculated), while the cash balance dropped by USD 65.7 million over six months (calculated). Weighted-average shares stood at 185.2 million against 161.7 million. The USD 116.8 million of cash is above the snapshot market value of USD 88.87 million, leaving a gap of USD 27.9 million (calculated). Neumora has no product sales yet, so its results depend on spending and financing. Risks include early-stage trial results, funding needs beyond third-quarter 2027, dilution and a Leadership transition. With a market value under USD 100 million, small-cap shares may be volatile and hard to trade.

Where Things Stand

Neumora Therapeutics, Inc. (NASDAQ:NMRA) heads into its report with a consensus EPS estimate of -0.19, a snapshot market value of USD 88.87 million and USD 116.8 million of cash on June 30, 2026. Management cut spending over the first six months, with research costs of USD 67.9 million against USD 90.9 million, and expects its funds to stretch into third-quarter 2027. Updates on NMRA-215, NMRA-511 and NMRA-898 are guided for fourth-quarter and second-half 2026, so remarks on timing may matter. This note is for information only and is not a recommendation to buy or sell.